Novo Nordisk Introduces Increased Dosage of Wegovy Injection Nationwide — Retail Analysts Consider Stock 'Significantly Undervalued'
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Source: stocktwits
WeGovy HD Approval: Novo has received approval for a higher dose of its WeGovy injection, which showed that 89% of participants achieved 5% or greater weight loss at 72 weeks in a recent clinical trial.
Pricing and Availability: The WeGovy HD injection will be priced at $399 per month and will be available through over 70,000 U.S. pharmacies, including Novo's own pharmacy services.
Market Competition: Novo launched its weight loss pill earlier this year to regain market share lost to competitors like Eli Lilly, which has been eroding its dominance in the weight loss medication market.
Stock Performance: Following the announcement of the WeGovy HD availability, Novo's stock saw a significant increase in retail chatter, although it remains undervalued according to some market analysts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 42.810
Low
42.00
Averages
54.67
High
70.00
Current: 42.810
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Oral Weight Loss Pill Approved in the UK
- Drug Approval: Novo Nordisk's oral GLP-1 therapy, Wegovy, has been approved in the UK, providing an alternative to injectable weight loss medications for obese or overweight adults, which is expected to significantly enhance market share.
- Clinical Trial Results: In the OASIS 4 phase 3 clinical trial, adults taking the 25 mg Wegovy pill experienced nearly a 14% weight loss over 64 weeks, compared to a mere ~2% decline in the placebo group, demonstrating substantial efficacy.
- Market Expansion Plans: This approval allows Novo Nordisk to launch the drug in its second market outside the U.S., with plans to introduce it in select markets in the second half of the year, further driving company growth.
- Industry Impact: The introduction of oral Wegovy is expected to alleviate sales decline pressures for Novo Nordisk and position the company more favorably in the weight loss medication market, enhancing its competitiveness in the global healthcare sector.
See More
Novo Nordisk's Wegovy Pill Approved in the UK
- Drug Approval Milestone: Novo Nordisk's Wegovy pill has been approved in the UK, marking the first daily GLP-1 receptor agonist for weight management, expected to be available via private prescription within weeks, representing a significant breakthrough in the obesity drug market.
- Surge in Prescriptions: Since its U.S. launch on January 5, 2026, the Wegovy pill has achieved over 3 million prescriptions in just over five months, demonstrating strong performance in the prescription drug market and further solidifying Novo Nordisk's market position.
- Cybersecurity Incident Investigation: Following the identification of an IT security incident, Novo Nordisk has initiated an investigation with external cybersecurity experts, and while core business operations remain unaffected, the company has implemented measures to protect its internal IT systems, highlighting its commitment to data security.
- Market Sentiment Shift: Despite the positive impact of Wegovy's approval, retail sentiment around NVO stock has shifted from 'extremely bullish' to 'bullish' in the past 24 hours, reflecting a cautious attitude among investors regarding the company's future prospects.
See More
RBC Capital Markets Upgrades Pfizer Rating
- Rating Upgrade: RBC Capital Markets upgraded Pfizer's stock rating from 'sell' to 'sector perform', indicating a recognition of Pfizer's current stock price, although they still refrain from recommending a buy, reflecting cautious market sentiment.
- Market Reaction: Pfizer's shares rose 2.8% to $26.23 by Thursday morning, demonstrating a positive market response to RBC's rating adjustment, highlighting investor interest in Pfizer's future performance.
- Revenue Potential: RBC anticipates that two late-stage cancer drugs from Pfizer could generate $1.2 billion and $2.7 billion in revenue, respectively, despite the company facing competitive pressures in the GLP-1 weight-loss drug market.
- Valuation Appeal: Even with forecasts of single-digit revenue and earnings declines over the next two years, Pfizer's current price-to-earnings ratio is only about nine times, and with a 6.7% dividend yield, the stock appears relatively cheap, suggesting investors need not rush to sell.
See More
U.S. Employers' Attitudes Toward GLP-1 Drug Coverage Survey
- Employer Coverage Intent: A survey by Business Group on Health reveals that about 10% of U.S. employers are unlikely to cover GLP-1 weight loss drugs next year due to cost concerns and insufficient evidence of clinical benefits.
- Cost Pressures: The survey indicates that 72% of employers currently covering GLP-1s plan to continue, but Ellen Kelsay highlights that soaring healthcare costs, particularly from GLP-1s and other prescriptions, are driving changes in coverage policies.
- Health Benefits Expectations: While over half of employers believe GLP-1 drugs will provide significant health benefits, few have observed tangible results, including a decrease in obesity rates reflected in employee claims.
- Market Demand Outlook: 87% of employers expect newly approved oral GLP-1 drugs to increase overall demand, impacting prices, with only 9% anticipating a price decline, indicating strong market demand for this drug class.
See More
Novo Nordisk's Wegovy Pill Surpasses 3M Prescriptions in Five Months
- Prescription Milestone: Novo Nordisk's oral weight loss therapy, Wegovy, has surpassed 3 million prescriptions in just five months post-launch in the U.S., demonstrating strong performance in the obesity drug market despite competition from Eli Lilly.
- Rapid Growth: The Wegovy pill achieved 1 million prescriptions within the first 10-12 weeks of its U.S. launch, followed by an additional 2 million prescriptions in the last 10 weeks, with CEO Mike Doustdar highlighting this acceleration amid increasing competition.
- Market Expansion: More than 80% of new prescriptions for Wegovy are from patients new to the GLP-1 drug class, indicating that the therapy is not only attracting new users but also expanding the overall obesity treatment market, thereby enhancing Novo Nordisk's market position.
- Sales Forecast Upgrade: TD Cowen raised its 2030 global sales estimate for GLP-1 drugs from $139 billion to $150 billion, with oral versions expected to contribute 14%, further validating Novo Nordisk's strategic significance in this sector.
See More
Foundayo Approved by FDA; Lilly to Seek Type 2 Diabetes Approval
- Clinical Trial Results: In three late-stage trials, Foundayo outperformed Novo Nordisk's semaglutide and AstraZeneca's dapagliflozin in blood sugar control and weight loss, with the 17.2 mg dose reducing blood sugar levels by 2.2 percentage points, demonstrating a statistically significant advantage.
- Market Expansion Potential: Lilly plans to submit Foundayo for U.S. regulatory approval for type 2 diabetes by the end of Q2, which is expected to expand the company's total addressable market by providing a convenient oral alternative for patients who prefer pills.
- Consistent Safety Data: Safety data across the three trials were consistent, with the most common side effects being mild-to-moderate gastrointestinal issues, and discontinuation rates remained in the low-to-mid teens, aligning with other oral GLP-1s.
- Positive Investor Sentiment: Lilly's shares closed about 2% higher on Monday and edged up after-hours, reflecting Wall Street's optimistic outlook on Foundayo as a potential first-line oral diabetes treatment, with the stock gaining approximately 49% over the past 12 months.
See More
Novo Nordisk's Oral Weight Loss Pill Approved in the UK
- Drug Approval: Novo Nordisk's oral GLP-1 therapy, Wegovy, has been approved in the UK, providing an alternative to injectable weight loss medications for obese or overweight adults, which is expected to significantly enhance market share.
- Clinical Trial Results: In the OASIS 4 phase 3 clinical trial, adults taking the 25 mg Wegovy pill experienced nearly a 14% weight loss over 64 weeks, compared to a mere ~2% decline in the placebo group, demonstrating substantial efficacy.
- Market Expansion Plans: This approval allows Novo Nordisk to launch the drug in its second market outside the U.S., with plans to introduce it in select markets in the second half of the year, further driving company growth.
- Industry Impact: The introduction of oral Wegovy is expected to alleviate sales decline pressures for Novo Nordisk and position the company more favorably in the weight loss medication market, enhancing its competitiveness in the global healthcare sector.
See More
Novo Nordisk's Wegovy Pill Approved in the UK
- Drug Approval Milestone: Novo Nordisk's Wegovy pill has been approved in the UK, marking the first daily GLP-1 receptor agonist for weight management, expected to be available via private prescription within weeks, representing a significant breakthrough in the obesity drug market.
- Surge in Prescriptions: Since its U.S. launch on January 5, 2026, the Wegovy pill has achieved over 3 million prescriptions in just over five months, demonstrating strong performance in the prescription drug market and further solidifying Novo Nordisk's market position.
- Cybersecurity Incident Investigation: Following the identification of an IT security incident, Novo Nordisk has initiated an investigation with external cybersecurity experts, and while core business operations remain unaffected, the company has implemented measures to protect its internal IT systems, highlighting its commitment to data security.
- Market Sentiment Shift: Despite the positive impact of Wegovy's approval, retail sentiment around NVO stock has shifted from 'extremely bullish' to 'bullish' in the past 24 hours, reflecting a cautious attitude among investors regarding the company's future prospects.
See More
RBC Capital Markets Upgrades Pfizer Rating
- Rating Upgrade: RBC Capital Markets upgraded Pfizer's stock rating from 'sell' to 'sector perform', indicating a recognition of Pfizer's current stock price, although they still refrain from recommending a buy, reflecting cautious market sentiment.
- Market Reaction: Pfizer's shares rose 2.8% to $26.23 by Thursday morning, demonstrating a positive market response to RBC's rating adjustment, highlighting investor interest in Pfizer's future performance.
- Revenue Potential: RBC anticipates that two late-stage cancer drugs from Pfizer could generate $1.2 billion and $2.7 billion in revenue, respectively, despite the company facing competitive pressures in the GLP-1 weight-loss drug market.
- Valuation Appeal: Even with forecasts of single-digit revenue and earnings declines over the next two years, Pfizer's current price-to-earnings ratio is only about nine times, and with a 6.7% dividend yield, the stock appears relatively cheap, suggesting investors need not rush to sell.
See More
U.S. Employers' Attitudes Toward GLP-1 Drug Coverage Survey
- Employer Coverage Intent: A survey by Business Group on Health reveals that about 10% of U.S. employers are unlikely to cover GLP-1 weight loss drugs next year due to cost concerns and insufficient evidence of clinical benefits.
- Cost Pressures: The survey indicates that 72% of employers currently covering GLP-1s plan to continue, but Ellen Kelsay highlights that soaring healthcare costs, particularly from GLP-1s and other prescriptions, are driving changes in coverage policies.
- Health Benefits Expectations: While over half of employers believe GLP-1 drugs will provide significant health benefits, few have observed tangible results, including a decrease in obesity rates reflected in employee claims.
- Market Demand Outlook: 87% of employers expect newly approved oral GLP-1 drugs to increase overall demand, impacting prices, with only 9% anticipating a price decline, indicating strong market demand for this drug class.
See More
Novo Nordisk's Wegovy Pill Surpasses 3M Prescriptions in Five Months
- Prescription Milestone: Novo Nordisk's oral weight loss therapy, Wegovy, has surpassed 3 million prescriptions in just five months post-launch in the U.S., demonstrating strong performance in the obesity drug market despite competition from Eli Lilly.
- Rapid Growth: The Wegovy pill achieved 1 million prescriptions within the first 10-12 weeks of its U.S. launch, followed by an additional 2 million prescriptions in the last 10 weeks, with CEO Mike Doustdar highlighting this acceleration amid increasing competition.
- Market Expansion: More than 80% of new prescriptions for Wegovy are from patients new to the GLP-1 drug class, indicating that the therapy is not only attracting new users but also expanding the overall obesity treatment market, thereby enhancing Novo Nordisk's market position.
- Sales Forecast Upgrade: TD Cowen raised its 2030 global sales estimate for GLP-1 drugs from $139 billion to $150 billion, with oral versions expected to contribute 14%, further validating Novo Nordisk's strategic significance in this sector.
See More
Foundayo Approved by FDA; Lilly to Seek Type 2 Diabetes Approval
- Clinical Trial Results: In three late-stage trials, Foundayo outperformed Novo Nordisk's semaglutide and AstraZeneca's dapagliflozin in blood sugar control and weight loss, with the 17.2 mg dose reducing blood sugar levels by 2.2 percentage points, demonstrating a statistically significant advantage.
- Market Expansion Potential: Lilly plans to submit Foundayo for U.S. regulatory approval for type 2 diabetes by the end of Q2, which is expected to expand the company's total addressable market by providing a convenient oral alternative for patients who prefer pills.
- Consistent Safety Data: Safety data across the three trials were consistent, with the most common side effects being mild-to-moderate gastrointestinal issues, and discontinuation rates remained in the low-to-mid teens, aligning with other oral GLP-1s.
- Positive Investor Sentiment: Lilly's shares closed about 2% higher on Monday and edged up after-hours, reflecting Wall Street's optimistic outlook on Foundayo as a potential first-line oral diabetes treatment, with the stock gaining approximately 49% over the past 12 months.
See More
